UTI: A practical approach


Leonor Echevarria, MD; FACP Infectious Disease Attending BUMC-P

Urinary Tract Infections Outline

- Definition
- Diagnosis
- Microbiology
- UTI (syndromes)
- Treatment

Urinary tract infection

- Uncomplicated UTI: infection in a premenopausal , non pregnant women with no urological abnormalities
- Complicated UTI: infection and a urinary tract with functional or structural abnormalities.



UTI : Clinical symptoms and presentation in adult

- Lower tract : cystitis
- Dysuria urinary urgency and frequency lateral fullness discomfort.
 - hemorrhagic cystitis bloody urine (10%)
- Upper tract: pyelonephritis
 -Fever, sweating
 -Nausea, vomiting, flank pain, dysuria
 Dehydration, hypotension
- Vaginal discharge (ho STD)

Diagnosis of UTI

- Collection of specimens
- Urinalysis microscopic examination
 - WBC upper limit 5-10 leukocytes hpf.
 - presence of bacteria
- Urine dipstick test : rapid screening test
 -Leukocyte esterase test (rapid pyuria screen)
 Se (detect >10 WBC/mL) 75-96%, Sp 94-98%
 -Nitrate->Nitrite test positive in only 25%
 Se ~20%, Sp 95%

QUESTION


• What are the indications for urine culture?

Diagnosis of UTI

- Indications for urine culture
 - -Pyelonephritis
 - complicated UTI
 - Recurrent UTI
 - Patients with multiple allergies
 - -Suspect MDRO


Microbiology of UTI

- E. coli 75-90%
- S. saprophyticus 5-15%
- Klebsiella, Proteus, Enterococcus, Pseudomonas small percentages



- Hospital acquired : Enterobacter, Klebsiella, Acinetobacter, Serratia, Citrobacter, Providencia, Pseudomonas, Enterococcus
- Anaerobes rarely cause UTI
- Candida increasingly recognized as a cause of UTI

Microbiology of UTI



Nature Reviews Microbiology 13, 269-284 (2015)

Urinary Tract Infections

- Acute uncomplicated cystitis
- Acute uncomplicated pyelonephritis
- Recurrent UTI
- Complicated UTI- sepsis
- CA UTI
- Candida UTI

Treatment of UTIs

- Acute uncomplicated cystitis
- Acute uncomplicated pyelonephritis


Clinical Practice Guidelines CID 2011;52 (1 March)

Treatment of UTIs

For AUC and AUP consider :

- Antimicrobial resistance
- Collateral damage
- -Cephalosporins linked to subsequent infections VRE, ESBL Klebsiella, Beta lacatamse R acinetobacter, C Dif
- -Fluoroquinolones linked to infection with MRSA and FQ R in GN

Clinical Practice Guidelines CID 2011;52 (1 March)



Clinical Practice Guidelines CID 2011:52 e103-e120

Acute uncomplicated pyelonephritis

- Urine culture and susceptibility testing
- Oral ciprofloxacin 500 BID x 7 days (w or wo initial IV). Resistance < 10%
- Oral TMP/SMX (160/800) if uropathogen known to be susceptible x 14 days. If susc not known initial IV (ceftriaxone or AG)
- Oral B- lactam less effective. If used initial IV (ceftriaxone or AG) 10-14 days

QUESTION

• Which are the FDA warnings for quinolones?

	CDC Warning on FQ Antibiotic use: Rolling Back Use for Patient Safety								
	ODE warning on I Q Millibiole use. Roning Dack Ose for I alent Salety								
	commendations state that risks of serious side effects with fluoroquinolones generally outweigh								
benefits	for patients with the following:								
a	Acute bacterial sinusitis								
b.	Acute exacerbation of chronic bronchitis								
с. 2 Тран	Uncomplicated UTI								
	A has determined that fluoroquinolones should be reserved for the previous three conditions only here are no alternative treatment options.								
	juinolones may be considered in the following scenarios:								
a. Patient with type 1 hypersensitivity reaction to both penicillin and cephalosporins									
b.	Definitive therapy for multidrug resistant organism in which the isolate is resistant to all beta-lactams								
	and susceptible to fluoroquinolone.								
с.	For bacteremia stepdown therapy in which organism is susceptible								
d.									
	outweigh the risk.								
	El a constructor de Marcola de Marcola de								
Lala 2009	Fluoroquinolone Boxed Warning increased risk of tendinitis and tendon runture								
July 2008 February 2011	 increased risk of tendinitis and tendon rupture increased risk of exacerbating muscle weakness related to Myasthenia gravis 								
August 2013	 increased fisk of exacerbating muscle weakness related to Myasthenia gravis increased potential risk for irreversible peripheral neuropathy 								
July 2016	 increased CNS effects ((i.e. anxiety, depression, hallucinations, suicidal thoughts, 								
July 2010	confusion)								
July 2018	 new mental health side effects updated to include ddisturbances in attention, 								
(new labeling	disorientation, agitation, nervousness, memory impairment and delirium								
change)	• serious blood sugar disturbances, particularly risk of coma with hyopglycemia								

Dec 20,2018 -Warning for aortic rupture and tearing in patients at risk (known aortic or arterial aneurysms,HTN,PVD,elderly,rare genetic conditions affecting collagen) Pasternak et al ,NEJM JW Gen Med May 1 2018 Daneman et al. BMJ Open 2015;5;e 010077 JAMA Intern Med 2015;175:1839 J AM Coll Cardiol 2018;72:1369

QUESTION

How do you define recurrent UTI?

Recurrent UTIs

- 2 or > episodes 6M or 3 or > in a year. Non pregnant adult women
- Relapse : If current infection is caused by same pathogen as the initial UTI and occurs within 2 weeks
- Re infection: If current infection is caused by a different strain than initial UTI of Urine culture was sterile

Recurrent UTI : Risk Factors

- Spermicidal products
- Sexually active
- Genetic factors
- Variations in innate immune system low CXCR1 and CxCR2 expression)

BMJ 2013;346:f3140

Recurrent uncomplicated Urinary Tract Infections in women AUA/CUA/SUFU

AUA American Urological Association CUA Canadian Urological Society SUFU Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

J Urol. 2019 Aug;202 (2): 282-289

Prophylactic daily antibiotics.

- TMP 100mg once daily
- TMP-SMX 40mg/200mg once daily
- TMP-SMX 40mg/200mg thrice weekly
- Nitrofurantoin monohydrate/macrocrystals 50mg daily
- Nitrofurantoin monohydrate/macrocrystals 100mg daily
- Cephalexin 125mg once daily
- Cephalexin 250mg once daily
- Fosfomycin 3g every 10 days

Preventive measures

- Antimicrobial prophylaxis
- Patient centered approach

Recurrent cystitis

Provide patient education regarding natural course of recurrent UTI Assess potential modifiable risk factors and family history Discuss patient preference regarding antimicrobial management Discuss non-antimicrobial measures

Acute management

Obtain urine culture if no previous culture

Start empiric oral therapy

Trimethoprim (in UK) 200 mg twice daily (or TMP-SMX DS in USA) for 3 days Nitrofurantoin 100 mg twice daily fo-5 days Fosfomycin 3 g, single dose (not available in UK)

Alternative regimens

Clprofloxacin 250 mg twice daily for 3 days β lactam (cefpodoxime, cefuroxime; dose varies by regimen) for 5 days

The choice between these agents should be individualized and based on patient history (microbiology, tolerance, previous response)

Alternative agents should be reserved for cases when a preferred agent cannot be used – for example, in patients with in vitro resistance, allergy, or lack of response

Prophylaxis

Antimicrobial prophylaxis Trimethoprim (in UK) 100 mg at bedtime TMP-SMX SS (in USA) at bedtime, three times a week, or postcoitally Nitrofurantoin 50-100 mg at bedtime or postcoitally Cephalexin 250 mg at bedtime or postcoitally Cefaclor 250 mg at bedtime

The choice of agent and dosing regimen (daily, three times a week, postcoitally) should be individualized and based on patient history (previous microbiology; timing of UTI to coitus; ease of daily versus intermittent dosing)

Expectant management

Consider patient initiated therapy Trimethoprim (in UK) 200 mg twice daily (or TMP-SMX DS in USA) for 3 days Nitrofurantoin 100 mg twice daily for 5 days

Other previously successful regimen

BMJ 2013;346:f3140

Non antimicrobial strategies

- Lactobacillus : L crispatus intravaginal suppositories, oral capsules with L rhamnosus GR-1 and L reuteri RC- 14
- Water ingestion >1.5 lt/day
- Estrogens
- Cranberries
- Urination before and after sexual activity
- Diet (alcalinizing agents and siderocalin)

Infect Dis Clin N Am 28 (2014) 135-147 CID 2013 : 57 719-24 Shields-Cutter RR et al. Human urinary composition controls antibacterial activity of siderocalin J Biol Chem 2015;290(26):15949-15960

Drug induced UTI's

- Recent reports of drug induced UTI's related to sodiumglucose coransporter 2 (SGLT2) inhibitors "flozins"
- Oral hypoglycemics that work by increasing the amount of glucose spilled in the urine
- Include canagliflozin (Invokana), empagliflozin (jardiance) and dapagliflozin (Farxiga)
- SGLT2 are likely NOT causing UTI but rather the increased urinary glucose concentration may be linked to infection severity (Doses > 10 mg dapaglifozin) (2)

www.fda.gov/Drugs/DrugSafety/ucm47

2.Donnan JR et al. CMAJ Open 2018; doi:10.9778/cmajo.20180111

Complicated UTIs

Initial evaluation:

- Detailed history- Previous UTI, prior ATB use, have you seen a urologist before?
- Physical exam Sepsis ?
- UA and Urine culture
- Imaging
- <u>If obstruction</u>
- Prompt urologic evaluation

Complicated UTIs

- Diabetes Mellitus
- Acute pyelonephritis
- Emphysematous pyelonephritis
- Renal abscess
- Renal papillary necrosis
- UTI in renal transplant recipients
- Nephrolithiasis
- Prostatitis

Diagnosis of CA-UTI

- In patients with indwelling urethral, indwelling supra pubic or intermittent catheterization
- Presence of symptoms or signs cw UTI with no other identified source of infection along with 10 ³ CFU/ml of ≥ 1 bacterial species in a single urine specimen.

Diagnosis of CA-UTI

- Signs and symptoms cw UTI include: new onset of worsening fever, rigors, altered mental status, malaise, or lethargy with no other identified cause, flank pain; CVA tenderness; acute hematuria; pelvic discomfort
- When catheter removed : dysuria, urgent or frequent urination, supra pubic pain or tenderness

CID 2010:50 (1 March) 625-63

Diagnosis of CA-UTI

- A urine culture should be obtained prior to initiating antimicrobial treatment
- If an indwelling catheter has been in place for > 2 weeks at the onset of CA-UTI and is still indicated, the catheter should be replaced and a urine sample sent from freshly placed catheter
- If catheter can be discontinued , a culture of voided midstream urine specimen should be obtained

CID 2010:50 (1 March) 625-63

Banner Clinical Practice

- Discuss with patient indication and risk of placing an indwelling urinary catheter and document in chart.
- Select an indication for the catheter when ordering.
 - Urinary retention or obstruction
 - U.O. monitoring in critically ill, incontinent, uncooperative
 - Peri-operatively for selected surgical procedures
 - Fluid challenge in patients with ARF
 - Urinary incontinence posing risk to patient
 - Prolonged immobilization
 - Palliative care in terminally ill
- Continuing the catheter requires daily renewal order.
 - Nursing will contact you on daily basis for indication and order
 - Exceptions include certain urologic/gyn/perineal procedures

CA UTIs


- Cefepime 2 gm IV q 12h, Pip/tazo 3.375 gr q 6h or IMP 500 mg q 6h
- Discontinue or exchange catheter
- Duration 5-14 days
- Shorter duration in uncomplicated UTI 3d
- Do not use moxifloxacin

Zosyn extended infusion

- Zosyn 4.5 gm IV q 6h will be automatically replaced 3.375 GM IV extended infusion (4hs) q 8h. MIC <16
- ER 30 min infusion will continue

CID 2013; 56(2): 272-282 J Pharm Pract.2011 Dec ;24(6):571-6 J Expert Opin Drug Metab Toxicol.2010 Aug; 6(8): 1017-31

	MAN, GINGER DOB:04/12/1958 Weight:28.80 kg (0) 67/28/2018	Gender:Female	6 HETAL AS Encounter:Septient Location:01.050; 0821; 01	985A				MRN(2048992 Heatheulle Fortal:Declined 07/27/18 F3N(51706943 Choical Research: LDS:20 days BHN Plan:	- 8
EL MOR VERA, POSSILIS, DEP	saaryo, opium, pencian, suraceoamoar	courn						Retands	ton Status Istory ✔ Admission ✔ Discha
	Orders Prior Ir	Reconciliation							StoriFormAr
r Nane/Details	olders rive to		Statue		5		-	The second s	Status
cations				-	1		-		Prescribed
				0	0	0	1	10 mg, 1 cap, Cral, Daly, for 30 days, 30 cap, 0 Refili(s) < Notes for Patient >	Prescroes
Iome Hedications			32.74	1			1		
	stended release)		Documented	0	0	0	e.		Document
alenae			Ordered	0	0	0			
mg, 2 tab, Oral, BID					24.50	on in	m.	Province of the second state of a black	Prescribe
				0	۲	0	-	400 mg, 2 tab, Chal, Caly, for JH days, 68 tab, 0 RefS(a) < Notes for Patient >	ries. ve
onazole			Ordered	0	0	0		The continued order status has changed since it was reconciled or replaced.	
mp, 7 teb, Cral, Daily					-		Π.	ninerarilla-tambactam (ninerarilla-tambactam 3 nm-0.375 nm intravenses injection)	Prescribe
				0	0	0	-	See Instructions, JJ Pippyback (2014, 34 unit(s), 0 Alex80(s) < Notes for Patient >	
	(extended interval))		Ordered	0	0	0		The continued order status has changed since it was reconciled or replaced.	
o un, in riggioloc, cerr Inisont			Ordered	0.00	1050	-	B .	prederiGORE (prederiSORE 5 mp oral tablet)	Prescribe
ig, 3 tab, Oral, Daily				0	0	~		15 mg, 3 tab, Oral, Daily, for 60 days, 180 tab, 0 Reflig) < Notes for Patient >	
			Ordered	0	0	0	D.		Prescribe
We want to all the				6	0	0	D.	VAMCOmycin (vancomycin 125 mg eral capsule)	Prescribe
			2,222	0.5	1.2	4	-	125 mg, 1 cap, Cral, QBH, for 34 days, 136 cap, 0 Refl(g) < Notes for Patient >	
			Orbered	0	0	۲			
A State of the second									
			Ordered	0	0	0			
otidese			Ordered	0	0	0			
lg, 1 taib, Oral, BID				10.00	1				
	IRN: Bood Gucose		Ordered	0	0	۲			
2954.			Ordered	0	0	0			
	cone		Ordered	-	-	_			
	colie		Groenes.	0	0	۲			
ose (Dextrose 50%)			Ordered	0	0	(.)			
im, 50 mL, TV Push, On Call, PRN: units	c pippa Glucabe		Ordered						
ounitis), I mi, SubQ, QBH (ht)				0	0	٢			
tivitamin Oral Daily			Ordered	0	0	۲			
	MACC CARLETAL - Varme, Durtable attennes Innee (Nedlacationes Innae (dickofrenses sodium e ge, Oral, 800 Innae (dickofrenses sodium e ge, Oral, Oral, Daily Innae (dickofrenses) Innae (d	:MOCC GRH RETALL + Nome:Details attents atten	Orders Prior to Reconciliation /tome,Details attemm once Predications	Status Status Intern.Dirtatic Status Status Documented Status Documented Status Ordered Status Ordered <td>Orders Prior to Reconciliation Trance (ficultrance codium extended release) Occurrent do grante action do gra</td> <td>Orders Prior to Reconciliation Status Image: Status</td> <td>Orders Prior to Reconciliation Status Image: Status</td> <td>Orders Pror to Reconciliation Status Image: Status</td> <td>Addres for the foreconductor Addres for the foreconductor Addres for the foreconductor The region of the foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor</td>	Orders Prior to Reconciliation Trance (ficultrance codium extended release) Occurrent do grante action do gra	Orders Prior to Reconciliation Status Image: Status	Orders Prior to Reconciliation Status Image: Status	Orders Pror to Reconciliation Status Image: Status	Addres for the foreconductor Addres for the foreconductor Addres for the foreconductor The region of the foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor Addres foreconductor



Candida UTI

- Asymptomatic candiduria almost always epresents colonization and elimination of underlying RF (catheter can erradicate candiduria..
- Candida cystitis fluconazole susc org. fluconazole 200 mg Po x 2 weeks + removal of catheter
- Symptomatic ascending candida pyeloneprhritis fluconazole 400 mg 2 weeks, elimination of obstruction
- Treatment of asymptomatic candiduria: Very low birth weight infants
 - Patients undergoing urologic procedures
 - Neutropenic patients

Clinical Practice Guideline Guideline for Candidiasis CID 2016 62,e1-e50 https://doi.org/10.1093/cid/civ933

Recommended reading

- Clinical Practice Guidelines CID 2011:52 e 103-120
- Urinary Catheter Guidelines CID 2010:50 625-663
- Infect Dis Clin N Am 28 (2014) 1-159
- Uncomplicated Urinary Tract Infection N Engl J Med 366;11
- In the Clinic. Urinary Tract Infection. Ann Intern Med 2017; 167: ITC 49-63